Skip to main content
. 2017 Jan 16;7(4):452–465. doi: 10.1016/j.jtcme.2016.12.006

Fig. 5.

Fig. 5

WRL-68 cell proliferation during AP, CX. CZ, EP and OS treatment for 24 h. Significant decrease (p < 0.05) in viability was observed starting from 0.5 mg/ml for AP (Fig. 5A), 1.0 mg/ml for CZ (Fig. 5C), EP (Fig. 5D) and OS (Fig. 5E). CX (Fig. 5B) was shown to inhibit cell proliferation at 5.0 mg/ml.